The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Abstract
Background Studies have reported a significant association between non-alcoholic fatty liver disease (NAFLD) and increased incidence of cardiovascular disease (CVD). However, the magnitude of the risk and whether this risk changes with the severity of NAFLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CVD events.Methods We systematically searched PubMed, Scopus, and Web of Science from database inception to July 1, 2021, to identify eligible observational studies examining the risk of incident CVD events amongst adult (age ≥18 years) individuals with and without NAFLD and in which NAFLD was diagnosed by imaging, International Classification of Diseases codes, or liver biopsy. The primary outcomes were CVD death, non-fatal CVD events, or both. Data from selected studies were extracted, and meta-analysis was performed using random-effects models to obtain summary hazard ratios (HRs) with 95% CIs. The quality of the evidence was assessed with the Cochrane risk of bias tool. This study is registered on Open Science Framework, number osf.io/5z7gf.Findings We identified 36 longitudinal studies with aggregate data on 5 802 226 middle-aged individuals (mean age 53 years [SD 7]) and 99 668 incident cases of fatal and non-fatal CVD events over a median follow-up of 6·5 years (IQR 5·0-10·2). NAFLD was associated with a moderately increased risk of fatal or non-fatal CVD events (pooled random-effects HR 1·45, 95% CI 1·31-1·61; I 2=86·18%). This risk markedly increased across the severity of NAFLD, especially the stage of fibrosis (pooled random-effects HR 2·50, 95% CI 1·68-3·72; I 2=73·84%). All risks were independent of age, sex, adiposity measures, diabetes, and other common cardiometabolic risk factors. Sensitivity analyses did not modify these results.Interpretation NAFLD is associated with an increased long-term risk of fatal or non-fatal CVD events. CVD risk is further increased with more advanced liver disease, especially with higher fibrosis stage. These results provide evidence that NAFLD might be an independent risk factor for CVD morbidity and mortality.Funding None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overall, individuals with MASLD have a higher risk of non-fatal cardiovascular disease (HR 1.40), 25”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although some studies indicated a higher risk of cardiovascular disease-related mortality (HR 1.30), 25,26 others did not con fi rm this result in the general population, but only in those with biopsy-proven MASH 24 or other risk factors like T2D. 15”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhou, Y. J., Li, Y. Y., Nie, Y. Q., Huang, C., & Cao, C. Y. (2011) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2011.00571.x · Cited by 80
RetractedThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,496
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429
Self-citationNonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,251
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Targher, G., Byrne, C. D., & Tilg, H. (2024) · Gut · doi:10.1136/gutjnl-2023-330595 · Cited by 1,082
Self-citationCurrent status and future trends of the global burden of MASLD
Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.007 · Cited by 781
Self-citationA Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes
Stefan, N., & Cusi, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00003-1 · Cited by 593
Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Neeland, I. J., Lim, S., Tchernof, A., Gastaldelli, A., Rangaswami, J., Ndumele, C. E., Powell-Wiley, T. M., & Després, J.-P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00563-5 · Cited by 463
Cusi, K. J., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 417
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki‐Järvinen, H., & Loomba, R. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 365
Metabolic Dysfunction–Associated Steatotic Liver Disease
Targher, G., Valenti, L., & Byrne, C. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412865 · Cited by 325
Self-citationNatural history and progression of metabolic dysfunction-associated steatotic liver disease
Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310
The role of hepatokines in NAFLD
Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H., & White, M. F. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.006 · Cited by 288
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
Tilg, H., Petta, S., Stefan, N., & Targher, G. (2025) · JAMA · doi:10.1001/jama.2025.19615 · Cited by 309
Self-citationMetabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Lee, H., Lee, H. A., Kim, E.-J., Kim, H. Y., Kim, H. C., Ahn, S. H., Lee, H., & Kim, S. U. (2023) · Gut · doi:10.1136/gutjnl-2023-331003 · Cited by 270
Hutchison, A. L., Tavaglione, F., Romeo, S., & Charlton, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.030 · Cited by 250
Pipitone, R. M., Ciccioli, C., Infantino, G., Mantia, C. L., Parisi, S., Tulone, A., Pennisi, G., Grimaudo, S., & Petta, S. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221145549 · Cited by 254
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K. J., Hilliard, M. E., Isaacs, D. M., et al. (2022) · Diabetes Care · doi:10.2337/dc23-s004 · Cited by 242
ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M. S., Balapattabi, K., Beverly, E. A., Early, K. B., Bruemmer, D., Cusi, K. J., Echouffo-Tcheugui, J. B., et al. (2024) · Diabetes Care · doi:10.2337/dc25-s004 · Cited by 226
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world
Henry, L. L., Paik, J. M., & Younossi, Z. M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17158 · Cited by 217
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Zhou, X., Targher, G., Byrne, C. D., Somers, V. K., Kim, S. U., Chahal, C. A. A., Wong, V. W., Cai, J., Shapiro, M. D., Eslam, M., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10543-8 · Cited by 203
Self-citationChew, N., Mehta, A., Goh, R. S. J., Zhang, A. A. Y., Chen, Y., Chong, B., Chew, H. S. J., Shabbir, A., Brown, A. C., Dimitriadis, G. K., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.070535 · Cited by 191
Moon, J. H., Jeong, S., Jang, H., Koo, B. K., & Kim, W. K. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102292 · Cited by 187
Kim, K., Hong, S., Han, K., & Park, C. (2024) · BMJ · doi:10.1136/bmj-2023-076388 · Cited by 182
Steatotic liver disease, MASLD and risk of chronic kidney disease
Bilson, J., Mantovani, A., Byrne, C. D., & Targher, G. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101506 · Cited by 179
Self-citationZhou, X., Cai, J., Targher, G., Byrne, C. D., Shapiro, M. D., Sung, K., Somers, V. K., Chahal, C. A. A., George, J., Chen, L., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01697-0 · Cited by 174
Self-citationElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Cusi, K. J., Ekhlaspour, L., Fleming, T. K., Hilliard, M. E., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s004 · Cited by 173
Horberg, M. A., Thompson, M., Agwu, A. L., Colasanti, J. A., Haddad, M. S., Jain, M. K., McComsey, G. A., Radix, A., Rakhmanina, N. Y., Short, W. R., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae479 · Cited by 169
Chan, K. E., Ong, E. Y. H., Chung, C. H., Ong, C. E. Y., Koh, B., Tan, D. J. H., Lim, W. H., Yong, J. N., Xiao, J., Wong, Z. Y., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.09.018 · Cited by 155
Non‐alcoholic fatty liver disease and type 2 diabetes: An update
Lee, C., Lui, D. T. W., & Lam, K. S. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13756 · Cited by 139
Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., Bonapace, S., Rossi, A., Tilg, H., Byrne, C. D., & Targher, G. (2023) · Gut · doi:10.1136/gutjnl-2022-327672 · Cited by 128
Self-citationRelationship between NAFLD and coronary artery disease: A Mendelian randomization study
Ren, Z., Simons, P. I. H. G., Wesselius, A., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2022) · Hepatology · doi:10.1002/hep.32534 · Cited by 123
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease
Mantovani, A., Byrne, C. D., Benfari, G., Bonapace, S., Simon, T. G., & Targher, G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.007 · Cited by 115
Self-citationByrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 113
Self-citationCauses and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Konyn, P., Ahmed, A., & Kim, D. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0351 · Cited by 100
Ng, C. H., Chan, K. E., Chin, Y. H., Zeng, R. W., Tsai, P. C., Lim, W. H., Tan, D. J. H., Khoo, C. M., Goh, L. H., Ling, Z. J., et al. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0096 · Cited by 95
Le, M. H., Le, D. M., Baez, T. C., Dang, H., Nguyen, V. H., Lee, K., Stave, C. D., Ito, T., Wu, Y., Yeo, Y. H., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0485 · Cited by 92
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Martin, A., Lang, S., Goeser, T., Demir, M., Steffen, H., & Kasper, P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01028-4 · Cited by 93
Pennisi, G., Enea, M., Pandolfo, A., Celsa, C., Antonucci, M., Ciccioli, C., Infantino, G., Mantia, C. L., Parisi, S., Tulone, A., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.06.013 · Cited by 90
Ergothioneine: an underrecognised dietary micronutrient required for healthy ageing?
Tian, X., Thorne, J. L., & Moore, J. B. (2023) · British Journal Of Nutrition · doi:10.1017/s0007114522003592 · Cited by 90
Diabetes and cirrhosis: Current concepts on diagnosis and management
Castéra, L., & Cusi, K. J. (2023) · Hepatology · doi:10.1097/hep.0000000000000263 · Cited by 87
Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)
Zhao, Y., Zhou, Y., Wang, D., Huang, Z., Xiao, X., Zheng, Q., Li, S., Long, D., & Feng, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417514 · Cited by 89
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s004 · Cited by 90
Fan, J., Xu, X., Yang, R.-X., Nan, Y., Wei, L., Jia, J., Zhuang, H., Shi, J., Li, X., Cm, S., et al. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00311 · Cited by 92
Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study
Peng, H., Wang, S., Wang, M., Ye, Y., Xue, E. C., Chen, X., Wang, X., Fan, M., Gao, W., Qin, X., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155220 · Cited by 83
Risk factors in nonalcoholic fatty liver disease
Ko, E., Yoon, E. L., & Jun, D. W. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0398 · Cited by 83
Management of NAFLD in primary care settings
Wong, V. W., Zelber‐Sagi, S., Cusi, K. J., Carrieri, P., Wright, E. E., Crespo, J., & Lazarus, J. V. (2022) · Liver International · doi:10.1111/liv.15404 · Cited by 84
NASH drug treatment development: challenges and lessons
Tilg, H., Byrne, C. D., & Targher, G. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00159-0 · Cited by 81
Self-citationMaestri, M., Santopaolo, F., Pompili, M., Gasbarrini, A., & Ponziani, F. R. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1110536 · Cited by 76
Lonardo, A., Mantovani, A., Targher, G., & Baffy, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113320 · Cited by 76
Self-citationSemmler, G., Balcar, L., Wernly, S., Völkerer, A., Semmler, L., Hauptmann, L., Wernly, B., Aigner, E. S., Niederseer, D., & Datz, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244405 · Cited by 77
Nonalcoholic Fatty Liver Disease: Current Global Burden
El‐Kassas, M., Cabezas, J., Iruzubieta, P., Zheng, M., Arab, J. P., & Awad, A. (2022) · Seminars in Liver Disease · doi:10.1055/a-1862-9088 · Cited by 73
Díaz, L. A., Fuentes–López, E., Ayares, G., Idalsoaga, F. J., Arnold, J., Márquez‐Lomas, A., Ramírez, C., Medel, M. P., Viñuela, F., Lacalle, L., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00008-5 · Cited by 73
Risk of cardiovascular disease and loss in life expectancy in NAFLD
Shang, Y., Nasr, P., Widman, L., & Hagström, H. (2022) · Hepatology · doi:10.1002/hep.32519 · Cited by 73
Decoding the Liver-Heart Axis in Cardiometabolic Diseases
Capone, F., Vacca, A., Bidault, G., Sarver, D. C., Kamińska, D., Strocchi, S., Vidal‐Puig, A., Greco, C. M., Lusis, A. J., & Schiattarella, G. G. (2025) · Circulation Research · doi:10.1161/circresaha.125.325492 · Cited by 76
Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation
Lonardo, A., Mantovani, A., Petta, S., Carraro, A., Byrne, C. D., & Targher, G. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00711-5 · Cited by 69
Self-citationAhmed, A., Cule, M., Bell, J. D., Sattar, N. A., & Yaghootkar, H. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.030 · Cited by 66
MAFLD as part of systemic metabolic dysregulation
Zhao, J., Liu, L., Cao, Y., Gao, X., Targher, G., Byrne, C. D., Sun, D., & Zheng, M. (2024) · Hepatology International · doi:10.1007/s12072-024-10660-y · Cited by 62
Self-citationDiagnosis and Management of Nonalcoholic Fatty Liver Disease
Leung, P. B. K., Davis, A. M., & Kumar, S. R. (2023) · JAMA · doi:10.1001/jama.2023.17935 · Cited by 60
Zhang, L., El-Shabrawi, M. H. F., Baur, L. A., Byrne, C. D., Targher, G., Kehar, M., Porta, G., Lee, W. S., Lefere, S., Turan, S., et al. (2024) · Med · doi:10.1016/j.medj.2024.03.017 · Cited by 59
Self-citationXiao, J., Ng, C. H., Chan, K. E., Fu, C., Tay, P., Yong, J. N., Lim, W. H., Tan, D. J. H., Syn, N., Wong, Z. Y., et al. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.006 · Cited by 56
Mocciaro, G., Allison, M., Jenkins, B., Azzu, V., Huang‐Doran, I., Herrera-Marcos, L. V., Hall, Z., Murgia, A., Davies, S. E., Frontini, M., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101728 · Cited by 56
Forlano, R., Stanic, T., Jayawardana, S., Mullish, B. H., Yee, M. S., Mossialos, E. A., Goldin, R. D., Petta, S., Tsochatzis, E. A., Thursz, M. R., et al. (2023) · Liver International · doi:10.1111/liv.15730 · Cited by 55
Gries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 59
Self-citationSeo, Y., Pοlyzos, S. A., Park, K., & Mantzoros, C. S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.026 · Cited by 54
Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
Castillo-Núñez, Y., Almeda‐Valdés, P., González-Gálvez, G., & Arechavaleta-Granell, M. D. R. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01542-6 · Cited by 53
Sohn, W., Lee, Y., Kim, S. S., Kim, J. H., Jin, Y., Kim, G., Sung, P. S., Yoo, J., Chang, Y. W., Lee, E. J., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0045 · Cited by 53
MAFLD and CKD: An Updated Narrative Review
Mantovani, A., Lombardi, R., Cattazzo, F., Zusi, C., Cappelli, D., & Dalbeni, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137007 · Cited by 52
Self-citationKim, S., Oh, J. S., Shin, J. I., Aalruz, H., Abbas, N., Babatope, A. E., Aboagye, R. G., Abohashem, S., Abu‐Zaid, A., Addo, I. Y., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00011-7 · Cited by 59
Chew, N., Ng, C. H., Muthiah, M. D., & Sanyal, A. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01027-5 · Cited by 49
Mantovani, A., Dalbeni, A., Beatrice, G., Cappelli, D., & Peralta, F. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040968 · Cited by 46
Self-citationCardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease
Simon, T. G., Roelstraete, B., Alkhouri, N., Hagström, H., Sundström, J., & Ludvigsson, J. F. (2022) · Gut · doi:10.1136/gutjnl-2022-328105 · Cited by 45
Self-citationMoreira, R. O., Valério, C. M., Villela‐Nogueira, C. A., Cercato, C., Gerchman, F., Lottenberg, A. M., Godoy‐Matos, A. F., Oliveira, R. D. A., Brandão‐Mello, C. E., Álvares‐da‐Silva, M. R., et al. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0123 · Cited by 45
Sex and Gender Differences in Liver Fibrosis: Pathomechanisms and Clinical Outcomes
Jamalinia, M., Lonardo, A., & Weiskirchen, R. (2024) · Fibrosis · doi:10.70322/fibrosis.2024.10006 · Cited by 44
Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2110864 · Cited by 42
Remnant cholesterol has a non-linear association with non-alcoholic fatty liver disease
Chen, J., Su, Y., Su, X., & Luo, F. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110733 · Cited by 42
Zisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 44
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lubel, J. S., Hodge, A., & Roberts, S. K. (2023) · Nutrients · doi:10.3390/nu15030687 · Cited by 45
Møller, S., Kimer, N., Hove, J. D., Barløse, M., & Gluud, L. L. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae306 · Cited by 44
NAFLD: An Emerging Causal Factor for Cardiovascular Disease
Li, M., Wang, H., Zhang, X., Cai, J., & Li, H. (2023) · Physiology · doi:10.1152/physiol.00013.2023 · Cited by 41
Martínez‐Domínguez, S. J., García, S. G., Gargallo-Puyuelo, C. J., Llera, B. G., Callau, P., Mendi, C., Arroyo, M., Simón-Marco, M. Á., Ampuero, J., & Gomollón, F. (2023) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad175 · Cited by 40
Deng, M., Wen, Y., Yan, J., Fan, Y., Wang, Z., Zhang, R., Ren, L., Ba, Y., Wang, H., Lü, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03129-6 · Cited by 40
Cuthbertson, D. J., Keating, S. E., Pugh, C. J. A., Owen, P. J., Kemp, G. J., Umpleby, M., Geyer, N. G., Chinchilli, V. M., & Stine, J. G. (2024) · Liver International · doi:10.1111/liv.15947 · Cited by 38
Mantovani, A., Morieri, M. L., Aldigeri, R., Palmisano, L., Masulli, M., Bonomo, K., Baroni, M. G., Cossu, E., Cimini, F. A., Cavallo, M. G., et al. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101497 · Cited by 39
Self-citationRatti, C., Malaguti, M., D’Aniello, E., Bellasi, A., & Sanna, G. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120495 · Cited by 42
High-density lipoproteins and non-alcoholic fatty liver disease
Hoekstra, M., & Eck, M. V. (2023) · Atherosclerosis Plus · doi:10.1016/j.athplu.2023.08.001 · Cited by 40
Mantovani, A., Morandin, R., Sani, E., Fiorio, V., Shtembari, E., Bonapace, S., Petta, S., Pοlyzos, S. A., Byrne, C. D., & Targher, G. (2024) · Liver International · doi:10.1111/liv.16218 · Cited by 37
Self-citationKey takeaways from the updated multidisciplinary European MASLD guidelines
Horn, P., & Tacke, F. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100196 · Cited by 40
Godoy‐Matos, A. F., Valério, C. M., Júnior, W. S. D. S., Neto, J. M. D. A., Sposito, A. C., & Suassuna, J. H. R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01796-4 · Cited by 43
Jamalinia, M., Zare, F., Mantovani, A., Targher, G., & Lonardo, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16568 · Cited by 39
Self-citationBarchetta, I., Lubrano, C., Cimini, F. A., Dule, S., Passarella, G., Dellanno, A., Biasio, A., Leonetti, F., Silecchia, G., Lenzi, A., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10461-1 · Cited by 37
The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
Francisco Barrera, M., Uribe, J., Olvares, N., Huerta, P., Cabrera, D., & Romero‐Gómez, M. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101501 · Cited by 38
Cho, Y., Chang, Y., Ryu, S., Jung, H. S., Kim, C., Oh, H., Kim, M. K., Sohn, W., Shin, H. C., Wild, S. H., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1975 · Cited by 36
Self-citationMASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials
Zannad, F. M., Sanyal, A. J., Butler, J., Ferreira, J. P., Girerd, N., Miller, V., Pandey, A., Parikh, C. R., Ratziu, V., Younossi, Z. M., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13793 · Cited by 38
Yeung, S. L. A., Borges, M. C., Wong, T. H. T., Lawlor, D. A., & Schooling, C. M. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac212 · Cited by 35
Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis
Huang, S., Bao, Y., Zhang, N., Niu, R., & Tian, L. (2023) · Endocrine · doi:10.1007/s12020-023-03351-5 · Cited by 35
Miyamori, D., Tanaka, M., Sato, T., Endo, K., Mori, K., Mikami, T., Hosaka, I., Hanawa, N., Ohnishi, H., & Furuhashi, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030269 · Cited by 34
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., & Bril, F. (2024) · Metabolites · doi:10.3390/metabo14010040 · Cited by 34
Self-citationNAFLD as a continuous driver in the whole spectrum of vascular disease
Li, W., Liu, J., Cai, J., Zhang, X., Zhang, P., She, Z., Chen, S., & Li, H. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.10.007 · Cited by 34
Endothelial Dysfunction in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Theofilis, P., Vordoni, A., Nakas, N., & Kalaitzidis, R. (2022) · Life · doi:10.3390/life12050718 · Cited by 34
Baratta, F., D’Erasmo, L., Bini, S., Pastori, D., Angelico, F., Ben, M. D., Arca, M., & Costanzo, A. D. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.011 · Cited by 35
Metadata
- Authors
- Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G.
- Affiliations
- University of Verona (IT)
- Harvard University (US)
- Southampton General Hospital (GB)
- Corresponding author
- Targher, Giovanni
- ORCID
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 6
- Issue
- 11
- Pages
- 903-913
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W3201276384
- Cited by
- 674
- References
- 75
- Citations by year
- 2026: 160 · 2025: 151 · 2024: 141 · 2023: 122 · 2022: 95 · 2021: 4
- FWCI
- 13.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- The Lancet. Gastroenterology & hepatology (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Funders
- National Institute for Health Research Southampton Biomedical Research Centre (IS-BRC-20004)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular mortality, cardiovascular events, liver fibrosis, disease severity, cardiometabolic risk factors, cardiovascular risk factors, middle-aged adults, NAFLD staging
- MeSH terms
- Cardiovascular Diseases, Humans, Risk Factors, Severity of Illness Index, Models, Statistical, Survival Analysis, Observational Studies as Topic, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
